Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Acusphere Inc 주요 수익원은 Mobile Virtual Network Operator이며, 최신 수익 발표에서 수익은 118,577,920입니다. 지역별로는 United States이 Acusphere Inc의 주요 시장이며, 수익은 137,141,832입니다.